USANA Health Sciences, Inc. (NYSE: USNA) announced financial results for its fiscal second quarter ended June 30, 2018.
Record second quarter net sales of $301.5 million, an increase of 17.3% year-over-year
Second quarter diluted earnings per share increased 46.2% year-over-year to $1.36 per share
Financial Performance
For the second quarter of 2018, net sales were $301.5 million, compared with $257.1 million in the prior-year period, a 17.3% increase year-over-year. Favorable currency exchange rates positively impacted net sales by $12.5 million for the quarter as compared to the prior-year.
Celavive, the Company’s new skincare line, contributed approximately $7 million in incremental sales for the quarter. In markets where Celavive has launched, skin and personal care products accounted for 9.5% of overall sales in the second quarter of 2018, versus 5.7% a year ago. The Company’s total number of active Customers increased 5.3% year-over-year to 597,000.
Net earnings for the second quarter increased 45.8% to $33.9 million, compared with net earnings of $23.3 million reported in the prior-year period. Earnings per diluted share increased to $1.36 per diluted share, an increase of 46.2% on a year-over-year basis.
The increase in net earnings was due primarily to higher net sales and lower relative operating expenses compared to the prior year period. Costs related to China and the Company’s internal investigation into its China operations were nominal during the second